A Review on the Mechanisms and Clinical Advances of JAK Inhibitors in the Treatment of Rosacea

Rosacea is a chronic inflammatory disease that primarily affects the facial area, with a complex pathogenesis and a variety of treatment options. In recent years, with deeper research into the pathogenesis of rosacea, it has been discovered that the Janus Kinase-Signal Transducer and Activator of Transcription (JAK-STAT) signalling pathway may be involved in the development of rosacea, and JAK inhibitors are expected to become a new therapeutic approach for rosacea. This paper reviews the mechanisms, clinical efficacy, and safety of JAK inhibitors in the treatment of rosacea.